Please assess the completion status of the following clinical trial:

Trial Title: LGX818 for Patients With BRAFV600 Mutated Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of melanoma and colorectal cancer (CRC)) or hematologic malignancies and is in need of treatment because of progression or relapse.~* Patient's tumor has been evaluated and pre-identified as having a tumor with a BRAFV600 mutation at a CLIA certified laboratory.~* Patient must have received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.~* Patient must have progressive and measurable disease per RECIST 1.1. or other appropriate hematological response criteria.~* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~Exclusion Criteria:~* Patient has received prior treatment with LGX818.~* Patients with Central Nerve System (CNS) metastasis or leptomeningeal carcinomatosis.~* Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug.~* Patients with acute or chronic pancreatitis.~* Patients with impaired cardiac function or clinically significant cardiac diseases.~* Patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LGX818 (Type: EXPERIMENTAL): LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).